US5234814A
(en)
*
|
1989-06-01 |
1993-08-10 |
Du Pont Merck Pharmaceutical Company |
Diagnostic assay for alzheimer's disease
|
US5652214A
(en)
*
|
1989-06-05 |
1997-07-29 |
Cephalon, Inc. |
Treating disorders by application of insulin-like growth factors and analogs
|
US6723699B1
(en)
|
1989-06-05 |
2004-04-20 |
Cephalon, Inc. |
Treating disorders by application of insulin-like growth factors and analogs
|
US6693076B1
(en)
|
1989-06-05 |
2004-02-17 |
Cephalon, Inc. |
Treating disorders by application of insulin-like growth factors and analogs
|
US5093317A
(en)
*
|
1989-06-05 |
1992-03-03 |
Cephalon, Inc. |
Treating disorders by application of insulin-like growth factor
|
US5527527A
(en)
*
|
1989-09-07 |
1996-06-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
US6329508B1
(en)
|
1989-09-07 |
2001-12-11 |
Alkermes, Inc. |
Transferrin receptor reactive chimeric antibodies
|
US5672683A
(en)
*
|
1989-09-07 |
1997-09-30 |
Alkermes, Inc. |
Transferrin neuropharmaceutical agent fusion protein
|
US5977307A
(en)
*
|
1989-09-07 |
1999-11-02 |
Alkermes, Inc. |
Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
|
US5182107A
(en)
*
|
1989-09-07 |
1993-01-26 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
WO1991007947A1
(en)
*
|
1989-12-05 |
1991-06-13 |
Ramsey Foundation |
Neurologic agents for nasal administration to the brain
|
US5624898A
(en)
|
1989-12-05 |
1997-04-29 |
Ramsey Foundation |
Method for administering neurologic agents to the brain
|
US6407061B1
(en)
|
1989-12-05 |
2002-06-18 |
Chiron Corporation |
Method for administering insulin-like growth factor to the brain
|
US5130129A
(en)
*
|
1990-03-06 |
1992-07-14 |
The Regents Of The University Of California |
Method for enhancing antibody transport through capillary barriers
|
DE69222303T2
(de)
|
1991-04-30 |
1998-01-22 |
Eukarion Inc |
Kationisierte antikörper gegen intrazelluläre eiweisse
|
CA2184242C
(en)
*
|
1994-02-28 |
2000-05-02 |
Jorg Kreuter |
Drug targeting system, method for preparing same and its use
|
US5639940A
(en)
|
1994-03-03 |
1997-06-17 |
Pharmaceutical Proteins Ltd. |
Production of fibrinogen in transgenic animals
|
US6709653B1
(en)
*
|
1994-09-16 |
2004-03-23 |
Human Genome Sciences, Inc. |
Antibodies specific for human inositol monophosphatase H1
|
GB9509620D0
(en)
|
1995-05-12 |
1995-07-05 |
Nat Blood Authority |
Transepithelial transport of molecular species
|
US6015555A
(en)
*
|
1995-05-19 |
2000-01-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
US6942963B1
(en)
|
1997-01-10 |
2005-09-13 |
Massachusetts Institute Of Technology |
Methods for identifying treatments for neurotoxicity in Alzheimer's disease caused by β-amyloid peptides
|
WO1998030229A1
(en)
|
1997-01-10 |
1998-07-16 |
Massachusetts Institute Of Technology |
TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE BY β-AMYLOID PEPTIDES
|
US6913745B1
(en)
|
1997-12-02 |
2005-07-05 |
Neuralab Limited |
Passive immunization of Alzheimer's disease
|
US6710226B1
(en)
|
1997-12-02 |
2004-03-23 |
Neuralab Limited |
Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
|
US6743427B1
(en)
|
1997-12-02 |
2004-06-01 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
US7790856B2
(en)
*
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
US7179892B2
(en)
*
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
TWI239847B
(en)
*
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
US6761888B1
(en)
*
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
US6923964B1
(en)
|
1997-12-02 |
2005-08-02 |
Neuralab Limited |
Active immunization of AScr for prion disorders
|
US6787523B1
(en)
|
1997-12-02 |
2004-09-07 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
US6750324B1
(en)
|
1997-12-02 |
2004-06-15 |
Neuralab Limited |
Humanized and chimeric N-terminal amyloid beta-antibodies
|
US20080050367A1
(en)
*
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
US20050059802A1
(en)
*
|
1998-04-07 |
2005-03-17 |
Neuralab Ltd |
Prevention and treatment of amyloidogenic disease
|
US20030147882A1
(en)
*
|
1998-05-21 |
2003-08-07 |
Alan Solomon |
Methods for amyloid removal using anti-amyloid antibodies
|
AU4007599A
(en)
*
|
1998-05-21 |
1999-12-06 |
University Of Tennessee Research Corporation, The |
Methods for amyloid removal using anti-amyloid antibodies
|
US7273618B2
(en)
|
1998-12-09 |
2007-09-25 |
Chiron Corporation |
Method for administering agents to the central nervous system
|
US6787637B1
(en)
|
1999-05-28 |
2004-09-07 |
Neuralab Limited |
N-Terminal amyloid-β antibodies
|
UA81216C2
(en)
*
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
AUPQ180499A0
(en)
*
|
1999-07-23 |
1999-08-19 |
Biomolecular Research Institute Limited |
Beta-amyloid peptide inhibitors
|
AU4178601A
(en)
*
|
2000-02-24 |
2001-09-03 |
Univ Washington |
Humanized antibodies that sequester abeta peptide
|
WO2002022776A2
(en)
|
2000-09-13 |
2002-03-21 |
Novo Nordisk A/S |
Human coagulation factor vii variants
|
US7067550B2
(en)
*
|
2000-11-03 |
2006-06-27 |
Massachusetts Institute Of Technology |
Treatments for neurotoxicity in Alzheimer's Disease
|
WO2002035987A2
(en)
*
|
2000-11-03 |
2002-05-10 |
Massachusetts Institute Of Technology |
METHODS FOR IDENTIFYING TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE CAUSED BY β-AMYLOID PEPTIDES
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
TWI255272B
(en)
*
|
2000-12-06 |
2006-05-21 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
ES2432967T3
(es)
|
2001-03-22 |
2013-12-05 |
Novo Nordisk Health Care Ag |
Derivados del Factor VII de coagulación
|
US20020172676A1
(en)
*
|
2001-05-16 |
2002-11-21 |
George Jackowski |
Method of treatment of alzheimer's disease and device therefor
|
DE60232880D1
(de)
|
2001-05-24 |
2009-08-20 |
Neuren Pharmaceuticals Ltd |
Gpe-analoga und peptidomimetika
|
US7605177B2
(en)
|
2001-05-24 |
2009-10-20 |
Neuren Pharmaceuticals Limited |
Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
|
US7714020B2
(en)
|
2001-05-24 |
2010-05-11 |
Neuren Pharmaceuticals Limited |
Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
|
US20030096748A1
(en)
*
|
2001-06-04 |
2003-05-22 |
The Regents Of The University Of Michigan |
Methods and compositions for the treatment of diseases associated with signal transduction aberrations
|
ES2391905T3
(es)
*
|
2001-08-17 |
2012-11-30 |
Washington University |
Método de ensayo para la enfermedad de alzheimer
|
US20030082191A1
(en)
*
|
2001-08-29 |
2003-05-01 |
Poduslo Joseph F. |
Treatment for central nervous system disorders
|
MY139983A
(en)
*
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
US7074893B2
(en)
*
|
2002-06-03 |
2006-07-11 |
Regents Of The University Of Michigan |
Methods and compositions for the treatment of diseases associated with signal transduction aberrations
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
KR20050118669A
(ko)
*
|
2003-02-01 |
2005-12-19 |
뉴랄랩 리미티드 |
가용성 a-베타에 대한 항체를 생성하기 위한 능동 면역화
|
WO2004071408A2
(en)
|
2003-02-10 |
2004-08-26 |
Applied Molecular Evolution, Inc. |
Aβ BINDING MOLECULES
|
CA2519020A1
(en)
|
2003-03-18 |
2004-09-30 |
Novo Nordisk Health Care Ag |
Method for the production of gla-residue containing serine proteases
|
TWI306458B
(en)
|
2003-05-30 |
2009-02-21 |
Elan Pharma Int Ltd |
Humanized antibodies that recognize beta amyloid peptide
|
JP4824559B2
(ja)
|
2003-09-09 |
2011-11-30 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
凝固因子viiポリペプチド
|
WO2005052006A2
(en)
|
2003-11-25 |
2005-06-09 |
The Government Of The United States, As Represented By The Secretary Of Health And Human Services |
Mutated anti-cd22 antibodies and immunoconjugates
|
US20050272068A1
(en)
*
|
2004-03-18 |
2005-12-08 |
The Brigham And Women's Hospital, Inc. |
UCH-L1 expression and cancer therapy
|
WO2005089502A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
WO2005089504A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
US20070293539A1
(en)
*
|
2004-03-18 |
2007-12-20 |
Lansbury Peter T |
Methods for the treatment of synucleinopathies
|
EP1732549A4
(de)
*
|
2004-03-18 |
2009-11-11 |
Brigham & Womens Hospital |
Verfahren zur behandlung von synucleinopathien
|
WO2005089515A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
TW200636066A
(en)
*
|
2004-12-15 |
2006-10-16 |
Elan Pharm Inc |
Humanized antibodies that recognize beta amyloid peptide
|
AR051800A1
(es)
*
|
2004-12-15 |
2007-02-07 |
Wyeth Corp |
Anticuerpos a beta usados en mejorar la cognicion
|
WO2006066089A1
(en)
*
|
2004-12-15 |
2006-06-22 |
Neuralab Limited |
Humanized amyloid beta antibodies for use in improving cognition
|
US20060194821A1
(en)
*
|
2005-02-18 |
2006-08-31 |
The Brigham And Women's Hospital, Inc. |
Compounds inhibiting the aggregation of superoxide dismutase-1
|
KR101374454B1
(ko)
|
2005-03-31 |
2014-03-17 |
추가이 세이야쿠 가부시키가이샤 |
회합제어에 의한 폴리펩티드 제조방법
|
CU23317A1
(es)
|
2005-07-22 |
2008-10-22 |
Ct De Investigacia N Y Desarro |
Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central
|
EP3006457B1
(de)
|
2005-07-29 |
2017-11-22 |
The Government of the United States of America, as represented by the Secretary of Health and Human Services |
Mutierte pseudomonas exotoxine mit reduzierter antigenizität
|
US8124397B2
(en)
*
|
2005-08-08 |
2012-02-28 |
Oregon Health & Science University |
Inactivating pathogens with oxidizing agents for vaccine production
|
WO2007027559A2
(en)
|
2005-08-29 |
2007-03-08 |
Shashoua Victor E |
Neuroprotective and neurorestorative methods and compositions
|
US20100130425A1
(en)
|
2005-09-09 |
2010-05-27 |
Oregon Health & Science University |
Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia
|
US20090055942A1
(en)
|
2005-09-14 |
2009-02-26 |
Novo Nordisk Healthcare A/G |
Human Coagulation Factor VII Polypeptides
|
PT1976877E
(pt)
|
2005-11-30 |
2014-04-29 |
Abbvie Inc |
Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
|
EP1954718B1
(de)
|
2005-11-30 |
2014-09-03 |
AbbVie Inc. |
Anti-a-globulomer-antikörper, antigen bindende gruppen davon, entsprechende hybridome, nukleinsäuren, vektoren, wirtszellen, verfahren zur herstellung dieser antikörper, zusammensetzungen, die diese antikörper enthalten, verwendungen dieser antikörper und verfahren zur verwendung dieser antikörper
|
ES2535856T3
(es)
|
2005-12-15 |
2015-05-18 |
Genentech, Inc. |
Métodos y composiciones para dirigirse a la poliubiquitina
|
CA2634598A1
(en)
|
2005-12-23 |
2007-07-05 |
Link Medicine Corporation |
Treatment of synucleinopathies
|
EP2397852B1
(de)
|
2006-03-14 |
2013-12-04 |
Oregon Health and Science University |
Methoden zur Detektion einer Mycobakterium tuberculosis Infektion
|
EP2009101B1
(de)
|
2006-03-31 |
2017-10-25 |
Chugai Seiyaku Kabushiki Kaisha |
Antikörpermodifikationsverfahren für die aufreinigung eines bispezifischen antikörpers
|
DK3056568T3
(da)
|
2006-03-31 |
2021-11-01 |
Chugai Pharmaceutical Co Ltd |
Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
|
US8784810B2
(en)
*
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
EP2016097A2
(de)
|
2006-05-04 |
2009-01-21 |
Genentech, Inc. |
Verfahren und zusammensetzungen in verbindung mit zpa-polypeptiden
|
WO2008011348A2
(en)
|
2006-07-14 |
2008-01-24 |
Ac Immune S.A. |
Humanized antibody against amyloid beta
|
SI2046833T1
(sl)
|
2006-07-14 |
2013-12-31 |
Ac Immune S.A. |
Humanizirano protitelo proti amiloidu beta
|
EP2695896B1
(de)
|
2006-10-06 |
2018-08-22 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Prävention von Gewebeischämie, damit in Zusammenhang stehende Verfahren und Zusammensetzungen
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
KR101160385B1
(ko)
*
|
2007-01-18 |
2012-07-10 |
일라이 릴리 앤드 캄파니 |
페길화된 Aβ FAB
|
US20080200441A1
(en)
*
|
2007-02-14 |
2008-08-21 |
University Of Southern California |
Estrogen receptor modulators associated pharmaceutical compositions and methods of use
|
US20100311767A1
(en)
|
2007-02-27 |
2010-12-09 |
Abbott Gmbh & Co. Kg |
Method for the treatment of amyloidoses
|
DK2918598T3
(en)
|
2007-02-28 |
2019-04-29 |
The Govt Of U S A As Represented By The Secretary Of The Dept Of Health And Human Services |
Brachyury polypeptides and methods of use
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
US20090004213A1
(en)
*
|
2007-03-26 |
2009-01-01 |
Immatics Biotechnologies Gmbh |
Combination therapy using active immunotherapy
|
KR20100016661A
(ko)
*
|
2007-04-18 |
2010-02-12 |
얀센 알츠하이머 이뮤노테라피 |
대뇌 아밀로이드 혈관병증의 예방 및 치료
|
US8003097B2
(en)
*
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
EP2157911A2
(de)
*
|
2007-05-16 |
2010-03-03 |
Yeda Research And Development Co. Ltd. |
Beurteilung einer störung der blut-gehirn-schranke
|
KR101600095B1
(ko)
|
2007-06-12 |
2016-03-07 |
에이씨 이뮨 에스.에이. |
모노클로널 항 베타 아밀로이드 항체
|
CN101820911B
(zh)
|
2007-06-12 |
2015-05-06 |
Ac免疫有限公司 |
β淀粉样蛋白的人源化抗体
|
EP2008666A1
(de)
|
2007-06-29 |
2008-12-31 |
Institut Pasteur |
Verwendung von VHH-Antikörpern zur Herstellung von Peptidvektoren zur Verabreichung einer relevanten Substanz und Anwendungen der Peptidvektoren
|
EP2182983B1
(de)
|
2007-07-27 |
2014-05-21 |
Janssen Alzheimer Immunotherapy |
Behandlung von amyloidogenen erkrankungen mittels humanisierter anti-abeta antikörper
|
PT2197903E
(pt)
*
|
2007-09-04 |
2015-01-02 |
Us Gov Health & Human Serv |
Delecções no domínio ii da exotoxina a de pseudomonas que reduzem toxicidade não específica
|
EP3789400A1
(de)
|
2007-09-26 |
2021-03-10 |
Chugai Seiyaku Kabushiki Kaisha |
Modifizierte antikörperkonstantregion
|
JP5334319B2
(ja)
*
|
2007-09-26 |
2013-11-06 |
中外製薬株式会社 |
Cdrのアミノ酸置換により抗体の等電点を改変する方法
|
SG178809A1
(en)
|
2007-10-05 |
2012-03-29 |
Genentech Inc |
Use of anti-amyloid beta antibody in ocular diseases
|
JO3076B1
(ar)
*
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
TWI580694B
(zh)
|
2007-11-30 |
2017-05-01 |
建南德克公司 |
抗-vegf抗體
|
CN101514335B
(zh)
|
2008-02-22 |
2013-04-17 |
中国科学院生物物理研究所 |
流感病毒聚合酶亚基pa的表达纯化及pa氨基端及pa羧基端与pb1氨基端多肽复合体的晶体结构
|
US8232402B2
(en)
*
|
2008-03-12 |
2012-07-31 |
Link Medicine Corporation |
Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
|
EP2143735A1
(de)
*
|
2008-07-10 |
2010-01-13 |
Institut Pasteur |
Variable Domänen von Schwerketten-Antikörpern, die sich gegen GFAPs richten
|
US8680020B2
(en)
|
2008-07-15 |
2014-03-25 |
Academia Sinica |
Glycan arrays on PTFE-like aluminum coated glass slides and related methods
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
KR102100066B1
(ko)
|
2008-10-14 |
2020-04-10 |
제넨테크, 인크. |
이뮤노글로불린 변이체 및 그의 용도
|
JP5836125B2
(ja)
|
2008-10-16 |
2015-12-24 |
ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション |
高分子量メラノーマ関連抗原に対する完全ヒト抗体およびその使用
|
AU2009308293B2
(en)
|
2008-10-22 |
2015-02-05 |
Genentech, Inc. |
Modulation of axon degeneration
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
EP2370436A1
(de)
*
|
2008-11-13 |
2011-10-05 |
Link Medicine Corporation |
Azachinolinonderivate und deren verwendungen
|
US20110060005A1
(en)
*
|
2008-11-13 |
2011-03-10 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
US20100331363A1
(en)
*
|
2008-11-13 |
2010-12-30 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
CA2744016C
(en)
|
2008-11-20 |
2018-12-11 |
Cambria Pharmaceuticals, Inc. |
Treatment of amyotrophic lateral sclerosis
|
BRPI0918204A2
(pt)
|
2008-12-23 |
2015-12-08 |
Genentech Inc |
igv variante composição farmaceutica e kit
|
JP2012515790A
(ja)
*
|
2009-01-23 |
2012-07-12 |
サーモディクス ファーマシューティカルズ, インコーポレイテッド |
微粒子製造のための連続二重エマルジョン工程
|
CN101792745B
(zh)
|
2009-02-04 |
2014-09-17 |
中国科学院生物物理研究所 |
流感病毒聚合酶亚基pa氨基端多肽的表达纯化及pa氨基端多肽的晶体结构
|
WO2010099472A2
(en)
|
2009-02-27 |
2010-09-02 |
The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services |
Spanx-b polypeptides and their use
|
US9562104B2
(en)
|
2009-03-10 |
2017-02-07 |
Baylor Research Institute |
Anti-CD40 antibodies
|
DK2406288T3
(en)
*
|
2009-03-10 |
2017-03-27 |
Baylor Res Inst |
ANTIGEN PRESENTING CELL-TARGETED VACCINES
|
CN108373509A
(zh)
*
|
2009-03-10 |
2018-08-07 |
贝勒研究院 |
靶向抗原呈递细胞的抗病毒疫苗
|
TWI544077B
(zh)
|
2009-03-19 |
2016-08-01 |
Chugai Pharmaceutical Co Ltd |
Antibody constant region change body
|
CA2798183C
(en)
|
2009-05-05 |
2018-04-03 |
Cambria Pharmaceuticals, Inc. |
Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis
|
MX2011013016A
(es)
|
2009-06-05 |
2012-04-20 |
Link Medicine Corp |
Derivados de aminopirrolidinona y usos de los mismos.
|
WO2011006982A2
(en)
|
2009-07-17 |
2011-01-20 |
Rigshospitalet |
Inhibitors of complement activation
|
US9147246B2
(en)
|
2009-08-18 |
2015-09-29 |
Ben-Gurion University Of The Negev Research And Development Authority |
Apparatus and method for analyzing stream of imaging data
|
WO2011031441A1
(en)
|
2009-08-28 |
2011-03-17 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Therapy with a chimeric molecule and a pro-apoptotic agent
|
ES2599076T3
(es)
|
2009-09-02 |
2017-01-31 |
Genentech, Inc. |
Smoothened mutante y métodos de utilización del mismo
|
WO2011032022A1
(en)
|
2009-09-11 |
2011-03-17 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Improved pseudomonas exotoxin a with reduced immunogenicity
|
CN103403026B
(zh)
|
2009-09-25 |
2016-05-11 |
美国政府(由卫生和人类服务部的部长所代表) |
Hiv-1中和抗体及其用途
|
WO2011047340A1
(en)
|
2009-10-16 |
2011-04-21 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
|
CN104043126A
(zh)
|
2009-10-22 |
2014-09-17 |
霍夫曼-拉罗奇有限公司 |
轴突变性的调节
|
EP2501397B1
(de)
|
2009-11-20 |
2017-10-04 |
Oregon Health and Science University |
Verfahren zum hervorrufen einer immunantwort auf tuberkulose
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
EP2509626B1
(de)
|
2009-12-11 |
2016-02-10 |
F.Hoffmann-La Roche Ag |
Anti-vegf-c-antikörper und verfahren zu ihrer verwendung
|
CA2784385A1
(en)
|
2009-12-23 |
2011-06-30 |
Genentech, Inc. |
Anti-bv8 antibodies and uses thereof
|
WO2011100455A1
(en)
|
2010-02-12 |
2011-08-18 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Inhibition of antibody responses to foreign proteins
|
US10435458B2
(en)
|
2010-03-04 |
2019-10-08 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variants with reduced Fcgammar binding
|
JP6148013B2
(ja)
|
2010-03-05 |
2017-06-14 |
リグショスピタレト |
補体活性化のキメラ抑制分子
|
WO2011112599A2
(en)
|
2010-03-12 |
2011-09-15 |
The United States Of America, As Represented By The Secretary. Department Of Health & Human Services |
Immunogenic pote peptides and methods of use
|
WO2011119920A2
(en)
|
2010-03-25 |
2011-09-29 |
Oregon Health & Science University |
Cmv glycoproteins and recombinant vectors
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
JP2013523182A
(ja)
|
2010-04-15 |
2013-06-17 |
アボット・ラボラトリーズ |
アミロイドベータ結合タンパク質
|
CN103068378B
(zh)
|
2010-05-10 |
2016-07-06 |
中央研究院 |
具有抗流感活性的扎那米韦膦酸酯同类物及其制备方法
|
ES2695899T3
(es)
|
2010-06-16 |
2019-01-11 |
Univ Pittsburgh Commonwealth Sys Higher Education |
Anticuerpos contra endoplasmina y su uso
|
RU2607368C2
(ru)
|
2010-07-30 |
2017-01-10 |
Ац Иммуне С.А. |
Безопасные и функциональные гуманизированные антитела
|
US9289488B2
(en)
|
2010-08-12 |
2016-03-22 |
Ac Immune Sa |
Vaccine engineering
|
EP2603524A1
(de)
|
2010-08-14 |
2013-06-19 |
AbbVie Inc. |
Amyloid-beta-bindende proteine
|
DK2625197T3
(en)
|
2010-10-05 |
2016-10-03 |
Genentech Inc |
Smoothened MUTANT AND METHODS OF USING THE SAME
|
HUE027649T2
(en)
|
2010-10-07 |
2016-10-28 |
Ac Immune Sa |
Phosphonus recognition antibodies
|
US9687447B2
(en)
|
2010-10-26 |
2017-06-27 |
Ac Immune S.A. |
Method for preparing liposome-based constructs
|
DK2644698T3
(en)
|
2010-11-17 |
2018-01-22 |
Chugai Pharmaceutical Co Ltd |
MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE WITH ALTERNATIVE FUNCTION TO BLOOD COAGULATION FACTOR FUNCTION VIII
|
MX352889B
(es)
|
2011-02-25 |
2017-12-13 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo de fc especifico para fcyriib.
|
WO2012135132A1
(en)
|
2011-03-25 |
2012-10-04 |
Baylor Research Institute |
Compositions and methods to immunize against hepatitis c virus
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
ES2666550T3
(es)
|
2011-04-19 |
2018-05-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticuerpos monoclonales humanos específicos para glipicano 3 y uso de los mismos
|
SG194787A1
(en)
|
2011-05-06 |
2013-12-30 |
Us Gov Health & Human Serv |
Recombinant immunotoxin targeting mesothelin
|
CA2832109C
(en)
|
2011-06-10 |
2021-07-06 |
Oregon Health & Science University |
Cmv glycoproteins and recombinant vectors
|
CA2840224C
(en)
|
2011-06-22 |
2019-08-13 |
The General Hospital Corporation |
Treatment of proteinopathies
|
HUE053664T2
(hu)
|
2011-07-18 |
2021-07-28 |
The United States Of America |
Eljárások és készítmények Polyomavírussal összefüggõ betegségek gátlására
|
WO2013039916A1
(en)
|
2011-09-12 |
2013-03-21 |
The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services |
Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
|
WO2013039792A1
(en)
|
2011-09-12 |
2013-03-21 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Immunogens based on an hiv-1 gp120 v1v2 epitope
|
AU2012216792A1
(en)
|
2011-09-12 |
2013-03-28 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
|
EP3939996A1
(de)
|
2011-09-30 |
2022-01-19 |
Chugai Seiyaku Kabushiki Kaisha |
Antigenbindende moleküle zur förderung der zersetzung von antigenen mit mehreren biologischen aktivitäten
|
TW201326209A
(zh)
|
2011-09-30 |
2013-07-01 |
Chugai Pharmaceutical Co Ltd |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
EP3275902A1
(de)
|
2011-10-04 |
2018-01-31 |
IGEM Therapeutics Limited |
Ige anti-hmw-maa antikörper
|
BR122021017560B1
(pt)
|
2011-10-07 |
2023-03-07 |
Katholieke Universiteit Leuven |
Anticorpo, polinucleotídeo, composição farmacêutica, usos de um anticorpo, método in vitro, método de detecção post-mortem de multimêros do fosfo-tau, método de detecção in vitro da formação de um complexo imunológico, kits de teste, linhagem celular isolada e método de detecção in vitro de multimêros de fosfo-tau
|
US10275680B2
(en)
|
2011-10-19 |
2019-04-30 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Magnetic resonance maps for analyzing tissue
|
EP2586461A1
(de)
|
2011-10-27 |
2013-05-01 |
Christopher L. Parks |
Von einem eingehüllten Virus abgeleitete Virenpartikel
|
SG11201403988WA
(en)
|
2012-02-09 |
2014-10-30 |
Var2 Pharmaceuticals Aps |
Targeting of chondroitin sulfate glycans
|
JP6216766B2
(ja)
|
2012-03-29 |
2017-10-18 |
ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO,a body corporate |
クリック核酸
|
JP6293731B2
(ja)
|
2012-04-05 |
2018-03-14 |
エーシー イミューン エス.エー. |
ヒト化タウ抗体
|
US9566329B2
(en)
|
2012-04-06 |
2017-02-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Live, attenuated rubella vector to express vaccine antigens
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
RU2014148732A
(ru)
|
2012-05-22 |
2016-07-20 |
Ф. Хоффманн-Ля Рош Аг |
Замещенные дипиридиламины и их применение
|
AU2013266398A1
(en)
|
2012-05-22 |
2015-01-22 |
Genentech, Inc. |
N-substituted benzamides and their use in the treatment of pain
|
WO2013181543A1
(en)
|
2012-06-01 |
2013-12-05 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
High-affinity monoclonal antibodies to glypican-3 and use thereof
|
ES2631608T3
(es)
|
2012-06-27 |
2017-09-01 |
International Aids Vaccine Initiative |
Variante de la glicoproteína Env del VIH-1
|
CN104797555B
(zh)
|
2012-07-06 |
2017-12-22 |
基因泰克公司 |
N‑取代的苯甲酰胺及其使用方法
|
CA2880701A1
(en)
|
2012-08-18 |
2014-02-27 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
WO2014031476A1
(en)
|
2012-08-21 |
2014-02-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin domain-specific monoclonal antibodies and use thereof
|
WO2014031762A1
(en)
|
2012-08-21 |
2014-02-27 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
US20150224181A1
(en)
|
2012-09-14 |
2015-08-13 |
The United States Of America As Represented By The Secretary Department Of Health And Human Se |
Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
|
AU2013324049B2
(en)
|
2012-09-27 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin antibodies and methods for eliciting potent antitumor activity
|
KR20150061647A
(ko)
|
2012-09-27 |
2015-06-04 |
에프. 호프만-라 로슈 아게 |
치환된 설폰아미드 화합물
|
US20150307865A1
(en)
|
2012-10-15 |
2015-10-29 |
Novo Nordisk Health Care Ag |
Coagulation factor vii polypeptides
|
WO2014062778A1
(en)
|
2012-10-19 |
2014-04-24 |
Bavarian Nordic, Inc. |
Methods and compositions for the treatment of cancer
|
US9775895B2
(en)
|
2012-12-12 |
2017-10-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
HIV therapeutics and methods of making and using same
|
CN104994874B
(zh)
|
2012-12-26 |
2017-04-12 |
安科协同公司 |
抗整联蛋白β1抗体组合物及其使用方法
|
BR112015016395A2
(pt)
|
2013-01-18 |
2017-07-11 |
Hoffmann La Roche |
pirazóis 3-substituídos e uso como inibidores de dlk
|
WO2014126921A1
(en)
|
2013-02-12 |
2014-08-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that neutralize norovirus
|
EP2968536B1
(de)
|
2013-03-13 |
2023-06-28 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Verfahren zur modulierung von chemotherapeutischer zytotoxizität
|
CN105263490B
(zh)
|
2013-03-14 |
2018-05-22 |
基因泰克公司 |
取代的三唑并吡啶及其使用方法
|
BR112015023262B8
(pt)
|
2013-03-15 |
2024-02-06 |
Ac Immune Sa |
Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo
|
JP6526627B2
(ja)
|
2013-04-24 |
2019-06-05 |
テル ハショメール メディカル リサーチ インフラストラクチャー アンド サービシズ リミテッド |
組織解析用の磁気共鳴マップ
|
RU2015147601A
(ru)
|
2013-05-01 |
2017-06-05 |
Ф. Хоффманн-Ля Рош Аг |
С-связанные гетероциклоалкилзамещенные пиримидины и их применения
|
IL296526A
(en)
|
2013-05-01 |
2022-11-01 |
Hoffmann La Roche |
Biheteroaryl compounds and their uses
|
WO2014182532A1
(en)
|
2013-05-07 |
2014-11-13 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Mesothelin-specific immunocytokine and use thereof
|
US10000556B2
(en)
|
2013-05-09 |
2018-06-19 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Single-domain VHH antibodies directed to norovirus GI.1 and GII.4 and their use
|
WO2014210397A1
(en)
|
2013-06-26 |
2014-12-31 |
Academia Sinica |
Rm2 antigens and use thereof
|
US9981030B2
(en)
|
2013-06-27 |
2018-05-29 |
Academia Sinica |
Glycan conjugates and use thereof
|
JP6242484B2
(ja)
|
2013-07-09 |
2017-12-06 |
デューク ユニバーシティー |
特定の改善されたヒト二重特異性EGFRvIII抗体結合分子
|
US20150065381A1
(en)
|
2013-09-05 |
2015-03-05 |
International Aids Vaccine Initiative |
Methods of identifying novel hiv-1 immunogens
|
CA2923579C
(en)
|
2013-09-06 |
2023-09-05 |
Academia Sinica |
Human inkt cell activation using glycolipids with altered glycosyl groups
|
US11465978B2
(en)
|
2013-09-11 |
2022-10-11 |
The Administrators Of The Tulane Educational Fund |
Anthranilic amides and the use thereof
|
JP6534615B2
(ja)
|
2013-09-27 |
2019-06-26 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
EP2873423B1
(de)
|
2013-10-07 |
2017-05-31 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
BR112016002012A2
(pt)
|
2013-10-11 |
2017-08-01 |
Hoffmann La Roche |
compostos de sulfonamida heterocíclica substituída úteis como moduladores de trpa1
|
JP6502931B2
(ja)
|
2013-10-11 |
2019-04-17 |
アメリカ合衆国 |
Tem8抗体およびその使用
|
WO2015065919A1
(en)
|
2013-10-28 |
2015-05-07 |
The Regents Of The University Of California |
Treatment of metastatic prostate cancer
|
EP3066118B1
(de)
|
2013-11-06 |
2020-01-08 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Alk-antikörper, konjugate und chimäre antigenrezeptoren und deren verwendung
|
MX2016008110A
(es)
|
2013-12-20 |
2016-08-19 |
Hoffmann La Roche |
Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
|
US9931393B2
(en)
|
2013-12-20 |
2018-04-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Immunogenic JC polyomavirus compositions and methods of use
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
WO2015106003A1
(en)
|
2014-01-08 |
2015-07-16 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Ras pathways as markers of protection against hiv and methods to improve vaccine efficacy
|
CA2936833A1
(en)
|
2014-01-13 |
2015-07-16 |
Baylor Research Institute |
Novel vaccines against hpv and hpv-related diseases
|
EP3659624B1
(de)
|
2014-01-15 |
2022-11-16 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Auf knorpel gerichtete wirkstoffe und deren verwendung
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
TW201620939A
(zh)
|
2014-01-16 |
2016-06-16 |
中央研究院 |
治療及檢測癌症之組合物及方法
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
DK3102197T3
(en)
|
2014-02-04 |
2018-11-19 |
Genentech Inc |
Smoothened mutant and methods for its use
|
JP6562942B2
(ja)
|
2014-03-27 |
2019-08-28 |
アカデミア シニカAcademia Sinica |
反応性標識化合物およびその使用
|
WO2015175704A1
(en)
|
2014-05-14 |
2015-11-19 |
The Regents Of The University Of California |
Inhibitors of bacterial dna gyrase with efficacy against gram-negative bacteria
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
WO2015184008A1
(en)
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Fucosidase from bacteroides and methods using the same
|
AU2015267045B2
(en)
|
2014-05-27 |
2021-02-25 |
Academia Sinica |
Anti-HER2 glycoantibodies and uses thereof
|
JP2017518989A
(ja)
|
2014-05-27 |
2017-07-13 |
アカデミア シニカAcademia Sinica |
抗cd20糖操作抗体群およびその使用
|
TWI732738B
(zh)
|
2014-05-28 |
2021-07-11 |
中央研究院 |
抗TNF-α醣抗體及其用途
|
WO2016007534A1
(en)
|
2014-07-07 |
2016-01-14 |
Genentech, Inc. |
Therapeutic compounds and methods of use thereof
|
US9683017B2
(en)
|
2014-07-17 |
2017-06-20 |
University Tennessee Research Foundation |
Inhibitory peptides of viral infection
|
CN106999578B
(zh)
|
2014-07-31 |
2022-03-04 |
美国政府(由卫生和人类服务部的部长所代表) |
针对epha4的人类单克隆抗体和其用途
|
US10213506B2
(en)
|
2014-08-26 |
2019-02-26 |
University Of Tennessee Research Foundation |
Targeting immunotherapy for amyloidosis
|
US10400015B2
(en)
|
2014-09-04 |
2019-09-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant HIV-1 envelope proteins and their use
|
CA2960712A1
(en)
|
2014-09-08 |
2016-03-17 |
Academia Sinica |
Human inkt cell activation using glycolipids
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
BR122020006907B8
(pt)
|
2014-10-23 |
2023-01-31 |
Singh Biotechnology Llc |
Anticorpo de domínio único anti-kras e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipetídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
|
US20170267784A1
(en)
|
2014-10-23 |
2017-09-21 |
Singh Molecular Medicine, Llc |
Single domain antibodies directed against intracellular antigens
|
EP3218397B8
(de)
|
2014-11-14 |
2021-04-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralisierende antikörper gegen ebola virus glykoprotein und deren verwendung
|
MX2017006663A
(es)
|
2014-11-19 |
2017-08-21 |
Axon Neuroscience Se |
Anticuerpos tau humanizados en enfermedad de alzheimer.
|
US10072070B2
(en)
|
2014-12-05 |
2018-09-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Potent anti-influenza A neuraminidase subtype N1 antibody
|
TWI779010B
(zh)
|
2014-12-19 |
2022-10-01 |
日商中外製藥股份有限公司 |
抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法
|
PT3233921T
(pt)
|
2014-12-19 |
2021-12-09 |
Chugai Pharmaceutical Co Ltd |
Anticorpos anti-c5 e processos para a sua utilização
|
US10420834B2
(en)
|
2014-12-24 |
2019-09-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant metapneumovirus F proteins and their use
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
AU2016209056B2
(en)
|
2015-01-24 |
2021-01-28 |
Academia Sinica |
Cancer markers and methods of use thereof
|
JP6779887B2
(ja)
|
2015-01-24 |
2020-11-04 |
アカデミア シニカAcademia Sinica |
新規なグリカンコンジュゲートおよびその使用方法
|
KR102620346B1
(ko)
|
2015-01-30 |
2024-01-02 |
아카데미아 시니카 |
증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법
|
JP2018512597A
(ja)
|
2015-02-04 |
2018-05-17 |
ジェネンテック, インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
US9969800B2
(en)
|
2015-02-05 |
2018-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
IL-8 antibodies
|
WO2016138160A1
(en)
|
2015-02-24 |
2016-09-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
|
AU2016224409B2
(en)
|
2015-02-27 |
2021-01-28 |
Chugai Seiyaku Kabushiki Kaisha |
Composition for treating IL-6-related diseases
|
CN107406462B
(zh)
|
2015-03-09 |
2020-11-10 |
豪夫迈·罗氏有限公司 |
三环dlk抑制剂及其用途
|
JP2018513123A
(ja)
|
2015-03-12 |
2018-05-24 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Rorガンマ阻害剤を用いてがんを治療するための方法
|
WO2016154003A1
(en)
|
2015-03-20 |
2016-09-29 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Neutralizing antibodies to gp120 and their use
|
EP3069730A3
(de)
|
2015-03-20 |
2017-03-15 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
EP3072901A1
(de)
|
2015-03-23 |
2016-09-28 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
JP7082484B2
(ja)
|
2015-04-01 |
2022-06-08 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
KR20180008761A
(ko)
|
2015-05-22 |
2018-01-24 |
제넨테크, 인크. |
치환된 벤즈아미드 및 이의 이용 방법
|
WO2016196975A1
(en)
|
2015-06-03 |
2016-12-08 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
CN108603170A
(zh)
|
2015-06-12 |
2018-09-28 |
莱蒂恩技术公司 |
用工程改造的t细胞治疗癌症的方法
|
CN108137477A
(zh)
|
2015-08-27 |
2018-06-08 |
基因泰克公司 |
治疗化合物及其使用方法
|
US10935544B2
(en)
|
2015-09-04 |
2021-03-02 |
Obi Pharma, Inc. |
Glycan arrays and method of use
|
CA2998132A1
(en)
|
2015-09-11 |
2017-03-16 |
Nascent Biotech, Inc. |
Enhanced delivery of drugs to the brain
|
CA2997809A1
(en)
|
2015-10-07 |
2017-04-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
|
CA3001306A1
(en)
|
2015-10-09 |
2017-04-13 |
Miltenyi Biotec Technology, Inc. |
Chimeric antigen receptors and methods of use
|
TWI746473B
(zh)
|
2015-11-02 |
2021-11-21 |
美商辛分子醫藥有限公司 |
針對細胞內抗原之單域抗體
|
WO2017079479A1
(en)
|
2015-11-03 |
2017-05-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human |
Neutralizing antibodies to hiv-1 gp41 and their use
|
EP3380466A1
(de)
|
2015-11-25 |
2018-10-03 |
Genentech, Inc. |
Substituierte benzamide als natriumkanalblocker
|
US11359009B2
(en)
|
2015-12-25 |
2022-06-14 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-myostatin antibodies and methods of use
|
EP3398965A4
(de)
|
2015-12-28 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur förderung der effizienz der reinigung von polypeptid mit fc-region
|
JP2019509721A
(ja)
|
2016-02-04 |
2019-04-11 |
キュリス,インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
CN109195996A
(zh)
|
2016-03-08 |
2019-01-11 |
中央研究院 |
N-聚醣及其阵列的模组化合成方法
|
AU2017233658B2
(en)
|
2016-03-14 |
2023-09-21 |
Chugai Seiyaku Kabushiki Kaisha |
Cell injury inducing therapeutic drug for use in cancer therapy
|
WO2017160599A1
(en)
|
2016-03-14 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of cd300b antagonists to treat sepsis and septic shock
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
CN109311995A
(zh)
|
2016-03-29 |
2019-02-05 |
台湾浩鼎生技股份有限公司 |
抗体、药物组合物和方法
|
EP3854782A1
(de)
|
2016-03-30 |
2021-07-28 |
Genentech, Inc. |
Substituierte benzamide und verfahren zur verwendung davon
|
BR112018071683A2
(pt)
|
2016-04-22 |
2019-02-19 |
Obi Pharma, Inc. |
método para tratar um câncer de mama, método para tratamento de um tumor em um paciente, método para tratar um indivíduo sofrendo com câncer por imunoterapia, método para induzir/melhorar uma resposta imune em um indivíduo, método para melhorar a vacina obi-822 induzida pela resposta imune em um indivíduo necessitando da mesma, método para identificar um paciente adequado para terapia do câncer e método para determinar o prognóstico do tratamento do câncer ou resposta do fármaco de um paciente
|
WO2017192589A1
(en)
|
2016-05-02 |
2017-11-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to influenza ha and their use and identification
|
WO2017196847A1
(en)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
|
US10744198B2
(en)
|
2016-05-10 |
2020-08-18 |
Najit Technologies, Inc. |
Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production
|
WO2017214182A1
(en)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
JP7043483B2
(ja)
|
2016-07-20 |
2022-03-29 |
エフ.ホフマン-ラ ロシュ アーゲー |
二環式プロリン化合物
|
EP3487849A1
(de)
|
2016-07-20 |
2019-05-29 |
H. Hoffnabb-La Roche Ag |
Sulfonylcycloalkylcarboxamidverbindungen als trpa1-modulatoren
|
KR20230117482A
(ko)
|
2016-07-27 |
2023-08-08 |
오비아이 파머 인코퍼레이티드 |
면역원성/치료 글리칸 조성물 및 그의 용도
|
KR102528998B1
(ko)
|
2016-07-29 |
2023-05-03 |
오비아이 파머 인코퍼레이티드 |
인간 항체, 제약 조성물 및 방법
|
EP3494135A1
(de)
|
2016-08-02 |
2019-06-12 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Gegen glypican-2 (gpc2) gerichtete monoklonale antikörper und verwendung davon
|
SG11201801024XA
(en)
|
2016-08-05 |
2018-05-30 |
Chugai Pharmaceutical Co Ltd |
Therapeutic or preventive compositions for il-8-related diseases
|
WO2018029288A1
(en)
|
2016-08-12 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Sulfonyl pyridyl trp inhibitors
|
CA3034057A1
(en)
|
2016-08-22 |
2018-03-01 |
CHO Pharma Inc. |
Antibodies, binding fragments, and methods of use
|
JP7160482B2
(ja)
|
2016-09-02 |
2022-10-25 |
レンティジェン・テクノロジー・インコーポレイテッド |
Duocarを用いてがんを処置するための組成物および方法
|
US10702589B2
(en)
|
2016-10-04 |
2020-07-07 |
Ann And Robert H. Lurie Children's Hospital Of Chicago |
Compositions and methods of treating neurological disorder and stress-induced conditions
|
WO2018071576A1
(en)
|
2016-10-14 |
2018-04-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Treatment of tumors by inhibition of cd300f
|
CN109843886B
(zh)
|
2016-10-17 |
2022-04-19 |
豪夫迈·罗氏有限公司 |
二环吡啶酮内酰胺及其使用方法
|
KR20190077103A
(ko)
|
2016-11-21 |
2019-07-02 |
오비아이 파머 인코퍼레이티드 |
접합된 생물학적 분자, 제약 조성물 및 방법
|
JP7171567B2
(ja)
|
2016-11-28 |
2022-11-15 |
エフ.ホフマン-ラ ロシュ アーゲー |
一過性受容体電位型チャネル阻害剤としてのオキサジアゾロン類
|
CN110023313B
(zh)
|
2016-12-02 |
2022-10-25 |
豪夫迈·罗氏有限公司 |
二环酰胺化合物及其使用方法
|
US11072607B2
(en)
|
2016-12-16 |
2021-07-27 |
Genentech, Inc. |
Inhibitors of RIP1 kinase and methods of use thereof
|
EP3554538A2
(de)
|
2016-12-16 |
2019-10-23 |
Institute for Research in Biomedicine |
Neuartige rekombinante rsv-f-präfusionsproteine und verwendungen davon
|
WO2018119279A1
(en)
|
2016-12-21 |
2018-06-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies specific for flt3 and uses thereof
|
JP6706394B1
(ja)
|
2017-01-09 |
2020-06-03 |
レンティジェン・テクノロジー・インコーポレイテッドLentigen Technology, Inc. |
抗メソセリン免疫療法によりがんを処置するための組成物および方法
|
EP3580235A1
(de)
|
2017-02-10 |
2019-12-18 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Neutralisierende antikörper gegen das plasmodium-falciparum-circumsporozoit-protein und verwendung davon
|
CN110461838B
(zh)
|
2017-03-07 |
2022-05-06 |
豪夫迈·罗氏有限公司 |
噁二唑瞬时受体电位通道抑制剂
|
AU2018240556A1
(en)
|
2017-03-24 |
2019-10-10 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD33 immunotherapy
|
CN110546148A
(zh)
|
2017-03-24 |
2019-12-06 |
基因泰克公司 |
作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物
|
MX2019011506A
(es)
|
2017-03-31 |
2019-11-01 |
Seattle Genetics Inc |
Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
|
BR112019022280A2
(pt)
|
2017-04-28 |
2020-05-19 |
Seattle Genetics Inc |
tratamento de cânceres de her2 positivo
|
WO2018203545A1
(ja)
|
2017-05-02 |
2018-11-08 |
国立研究開発法人国立精神・神経医療研究センター |
Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法
|
US11389480B2
(en)
|
2017-05-19 |
2022-07-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibody targeting TNFR2 for cancer immunotherapy
|
WO2019006280A1
(en)
|
2017-06-30 |
2019-01-03 |
Lentigen Technology, Inc. |
HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
|
WO2019005208A1
(en)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
|
EP3652178B1
(de)
|
2017-07-14 |
2024-01-24 |
F. Hoffmann-La Roche AG |
Bicyclische ketonverbindungen und verfahren zur verwendung davon
|
CA3071624A1
(en)
|
2017-07-31 |
2019-02-07 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapy
|
GB201712952D0
(en)
|
2017-08-11 |
2017-09-27 |
Univ Edinburgh |
Immunomodulatory agent
|
ES2960419T3
(es)
|
2017-09-15 |
2024-03-04 |
Lentigen Tech Inc |
Composiciones y métodos de tratamiento de cáncer con inmunoterapia anti-CD19
|
US10610585B2
(en)
|
2017-09-26 |
2020-04-07 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating and preventing HIV
|
RU2020114670A
(ru)
|
2017-10-11 |
2021-11-12 |
Ф. Хоффманн-Ля Рош Аг |
Бициклические соединения для применения в качестве ингибиторов rip1 киназы
|
WO2019079249A1
(en)
|
2017-10-16 |
2019-04-25 |
Lentigen Technology, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER WITH ANTI-CD22 IMMUNOTHERAPY
|
CA3078688A1
(en)
|
2017-10-31 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
Bicyclic sulfones and sulfoxides and methods of use thereof
|
US11235046B2
(en)
|
2017-11-04 |
2022-02-01 |
Nevada Research & Innovation Corporation |
Immunogenic conjugates and methods of use thereof
|
BR112020010903A2
(pt)
|
2017-11-30 |
2020-11-17 |
Hanmi Pharm. Co., Ltd. |
composto, sal de um composto de fórmula (i), composição farmacêutica, uso de uma composição farmacêutica, uso de um composto, método para preparar uma forma cristalina do sal
|
JP7377802B2
(ja)
|
2017-12-20 |
2023-11-10 |
レンティジェン・テクノロジー・インコーポレイテッド |
免疫療法を用いてhiv/aidsを処置するための組成物および方法
|
US20210079067A1
(en)
|
2018-01-02 |
2021-03-18 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
TW202000201A
(zh)
|
2018-02-20 |
2020-01-01 |
瑞士商赫孚孟拉羅股份公司 |
製備1-芳基磺醯基-吡咯啶-2-甲醯胺瞬時受體電位通道拮抗劑化合物及其結晶型式之方法
|
RU2020130795A
(ru)
|
2018-02-21 |
2022-03-21 |
Дзе Юнайтед Стэйтс Оф Америка, Эс Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз |
Нейтрализующие антитела к env вич-1 и их применение
|
EP3759098A1
(de)
|
2018-02-26 |
2021-01-06 |
Genentech, Inc. |
Pyridinsulfonamidverbindungen und deren verwendung gegen schmerz und verwandte störungen
|
US10710994B2
(en)
|
2018-03-19 |
2020-07-14 |
Genentech, Inc. |
Oxadiazole transient receptor potential channel inhibitors
|
US10947251B2
(en)
|
2018-03-30 |
2021-03-16 |
Genentech, Inc. |
Therapeutic compounds and methods of use thereof
|
CN112074519A
(zh)
|
2018-04-20 |
2020-12-11 |
豪夫迈·罗氏有限公司 |
作为rip1激酶抑制剂用于治疗e.g.肠易激综合征(ibs)的n-[4-氧代-2,3-二氢-1,5-苯并氧氮杂-3-基]-5,6-二氢-4h-吡咯并[1,2-b]吡唑-2-甲酰胺衍生物和有关化合物
|
TW202003490A
(zh)
|
2018-05-22 |
2020-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療性化合物及其使用方法
|
WO2019236590A1
(en)
|
2018-06-04 |
2019-12-12 |
University Of Maryland, Baltimore |
Methods for preventing acute kidney injury
|
US11203645B2
(en)
|
2018-06-27 |
2021-12-21 |
Obi Pharma, Inc. |
Glycosynthase variants for glycoprotein engineering and methods of use
|
CA3105694A1
(en)
|
2018-07-12 |
2020-01-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Affinity matured cd22-specific monoclonal antibody and uses thereof
|
WO2020012021A1
(en)
|
2018-07-13 |
2020-01-16 |
Varct Diagnostics Aps |
Isolation of circulating cells of fetal origin using recombinant malaria protein var2csa
|
US20210292428A1
(en)
|
2018-08-08 |
2021-09-23 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-2 and uses thereof
|
WO2020051099A1
(en)
|
2018-09-03 |
2020-03-12 |
Genentech, Inc. |
Carboxamide and sulfonamide derivatives useful as tead modulators
|
AU2019343184A1
(en)
|
2018-09-20 |
2021-04-15 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD123 immunotherapy
|
JP2022502043A
(ja)
|
2018-09-26 |
2022-01-11 |
レンティジェン・テクノロジー・インコーポレイテッドLentigen Technology, Inc. |
抗cd19/cd22免疫療法によりがんを処置するための組成物および方法
|
CN113412119A
(zh)
|
2018-11-30 |
2021-09-17 |
莱蒂恩技术公司 |
用于用抗cd38免疫治疗来治疗癌症的组合物和方法
|
AU2019393745A1
(en)
|
2018-12-04 |
2021-06-10 |
California Institute Of Technology |
HIV vaccine immunogens
|
EP3883609A2
(de)
|
2018-12-20 |
2021-09-29 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Glykoprotein-spezifische monoklonale antikörper des ebola-virus und deren verwendungen
|
US20220064324A1
(en)
|
2019-01-08 |
2022-03-03 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Cross species single domain antibodies targeting mesothelin for treating solid tumors
|
AR119673A1
(es)
|
2019-01-11 |
2022-01-05 |
Hoffmann La Roche |
Compuestos bicíclicos de cetona y métodos para utilizarlos
|
US20220098323A1
(en)
|
2019-01-22 |
2022-03-31 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-1 and methods of use
|
TW202042820A
(zh)
|
2019-01-28 |
2020-12-01 |
美商西雅圖遺傳學股份有限公司 |
以妥卡替尼(Tucatinib)治療乳癌之方法
|
JP2022524507A
(ja)
|
2019-03-06 |
2022-05-06 |
レンティジェン・テクノロジー・インコーポレイテッド |
自己駆動型キメラ抗原受容体を用いてがんを処置するための組成物および方法
|
CA3140102A1
(en)
|
2019-05-30 |
2020-12-03 |
Dina SCHNEIDER |
Compositions and methods for treating cancer with anti-bcma immunotherapy
|
AU2020299382A1
(en)
|
2019-07-02 |
2022-01-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind EGFRvIII and their use
|
WO2021080983A1
(en)
|
2019-10-21 |
2021-04-29 |
Seagen Inc. |
Methods of treating her2 positive breast cancer with tucatinib in combination with capecitabine and trastuzumab
|
WO2021081052A1
(en)
|
2019-10-22 |
2021-04-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
|
CA3155989A1
(en)
|
2019-11-13 |
2021-05-20 |
Jason Robert ZBIEG |
Therapeutic compounds and methods of use
|
US20220387618A1
(en)
|
2019-11-15 |
2022-12-08 |
Seagen Inc. |
Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
|
AU2020394842A1
(en)
|
2019-12-04 |
2022-06-30 |
Ac Immune Sa |
Novel molecules for therapy and diagnosis
|
JP2023506158A
(ja)
|
2019-12-12 |
2023-02-15 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
Cd276に特異的な抗体-薬物コンジュゲートおよびその使用
|
US20230057461A1
(en)
|
2020-01-27 |
2023-02-23 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
|
WO2021168292A1
(en)
|
2020-02-20 |
2021-08-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Epstein-barr virus monoclonal antibodies and uses thereof
|
EP4118237A1
(de)
|
2020-03-11 |
2023-01-18 |
Seagen Inc. |
Verfahren zur behandlung von her2-mutantem krebs mit tucatinib
|
US11497770B2
(en)
|
2020-06-22 |
2022-11-15 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
TW202221026A
(zh)
|
2020-08-14 |
2022-06-01 |
瑞士商Ac 免疫有限公司 |
人源化抗tdp-43結合分子及其用途
|
IL301405A
(en)
|
2020-09-28 |
2023-05-01 |
Seagen Inc |
Methods for treating solid tumors driven by HER2 alterations with toctinib in combination with an anti-HER2 antibody
|
MX2023003759A
(es)
|
2020-10-02 |
2023-04-24 |
Genentech Inc |
Proceso para la preparacion de compuestos de biheteroarilo y formas cristalinas de estos.
|
EP4229082A1
(de)
|
2020-10-16 |
2023-08-23 |
AC Immune SA |
Alpha-synuclein bindende antikörper zur therapie und diagnose
|
WO2022093745A1
(en)
|
2020-10-26 |
2022-05-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
CA3171093A1
(en)
|
2020-11-05 |
2022-05-12 |
Dina SCHNEIDER |
Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
|
IL302836A
(en)
|
2020-11-17 |
2023-07-01 |
Seagen Inc |
Methods for treating cancer with a combination of tocatinib and an anti-PD-1/anti-PD-L1 antibody
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
|
TW202302626A
(zh)
|
2021-02-15 |
2023-01-16 |
日商武田藥品工業股份有限公司 |
用於調節tgf-b信息傳導之細胞療法組成物及方法
|
US20240041978A1
(en)
|
2021-03-03 |
2024-02-08 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
La protein as a novel regulator of osteoclastogenesis
|
WO2022232612A1
(en)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Lassa virus-specific nanobodies and methods of their use
|
WO2022261017A1
(en)
|
2021-06-09 |
2022-12-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross species single domain antibodies targeting pd-l1 for treating solid tumors
|
WO2023281097A1
(en)
|
2021-07-09 |
2023-01-12 |
Immunic Ag |
Methods for treating cancer
|
WO2023028056A1
(en)
|
2021-08-24 |
2023-03-02 |
Genentech, Inc. |
3-amino piperidyl sodium channel inhibitors
|
WO2023028077A1
(en)
|
2021-08-24 |
2023-03-02 |
Genentech, Inc. |
Sodium channel inhibitors and methods of designing same
|
WO2023076881A1
(en)
|
2021-10-26 |
2023-05-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
|
US11492394B1
(en)
|
2021-10-29 |
2022-11-08 |
Nascent Biotech, Inc. |
Kits and containers for treating vimentin expressing tumors
|
WO2023097195A1
(en)
|
2021-11-24 |
2023-06-01 |
Genentech, Inc. |
Therapeutic indazole compounds and methods of use in the treatment of cancer
|
TW202340212A
(zh)
|
2021-11-24 |
2023-10-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
TW202342519A
(zh)
|
2022-02-16 |
2023-11-01 |
瑞士商Ac 免疫有限公司 |
人源化抗tdp-43結合分子及其用途
|
US20230338424A1
(en)
|
2022-03-02 |
2023-10-26 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
|
WO2023192827A1
(en)
|
2022-03-26 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bispecific antibodies to hiv-1 env and their use
|
WO2023192881A1
(en)
|
2022-03-28 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
WO2023194565A1
(en)
|
2022-04-08 |
2023-10-12 |
Ac Immune Sa |
Anti-tdp-43 binding molecules
|
WO2023201333A1
(en)
|
2022-04-14 |
2023-10-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bispecific antibodies to ebola virus glycoprotein and their use
|
WO2023230429A1
(en)
|
2022-05-22 |
2023-11-30 |
Seagen Inc. |
Methods of treating colorectal cancer with tucatinib in combination with an anti-her2 antibody
|
WO2024026107A2
(en)
|
2022-07-28 |
2024-02-01 |
Lentigen Technology, Inc. |
Chimeric antigen receptor therapies for treating solid tumors
|
WO2024030829A1
(en)
|
2022-08-01 |
2024-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
|
US20240075142A1
(en)
|
2022-08-26 |
2024-03-07 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Fully Human Anti-CD20/CD19 Immunotherapy
|
WO2024050399A1
(en)
|
2022-09-01 |
2024-03-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
|